288 related articles for article (PubMed ID: 23462201)
1. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
Morrissette DA; Stahl SM
CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
[TBL] [Abstract][Full Text] [Related]
2. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.
Citrome L
CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847
[TBL] [Abstract][Full Text] [Related]
3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
4. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
5. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
6. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
7. Improving treatment adherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
[TBL] [Abstract][Full Text] [Related]
8. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.
Tuninger E; Levander S
Acta Psychiatr Scand; 1997 Nov; 96(5):347-53. PubMed ID: 9395152
[TBL] [Abstract][Full Text] [Related]
10. Treatment adherence in schizophrenia and schizoaffective disorder.
Goff DC; Hill M; Freudenreich O
J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
[TBL] [Abstract][Full Text] [Related]
11. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic medication in the treatment of schizophrenia.
Kane JM
Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
[TBL] [Abstract][Full Text] [Related]
13. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
14. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
Kao YC; Liu YP
Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
[TBL] [Abstract][Full Text] [Related]
15. The attitude of patients towards antipsychotic depot treatment.
Heres S; Schmitz FS; Leucht S; Pajonk FG
Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
[TBL] [Abstract][Full Text] [Related]
16. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness.
Valenstein M; Kavanagh J; Lee T; Reilly P; Dalack GW; Grabowski J; Smelson D; Ronis DL; Ganoczy D; Woltmann E; Metreger T; Wolschon P; Jensen A; Poddig B; Blow FC
Schizophr Bull; 2011 Jul; 37(4):727-36. PubMed ID: 19933540
[TBL] [Abstract][Full Text] [Related]
17. [Lifelong relapse prevention with antipsychotics in schizophrenia].
Hasan A; Wobrock T
Psychiatr Prax; 2010 Sep; 37(6):268-70. PubMed ID: 20803409
[No Abstract] [Full Text] [Related]
18. All antipsychotics are equal, but some are more equal than others.
Volavka J; Citrome L
J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959
[No Abstract] [Full Text] [Related]
19. [RÉALITÉ LT, a pharmacoepidemiological study of semiology and therapeutic strategy of patients with schizophrenia treated by antipsychotic loxapine in routine clinical practice].
Cousin FR; Samuelian JC; Saoud M; Schmitt L; Vacheron MN; Vidailhet P; Augendre J; Walter M; Tonelli I; Pascal JC
Encephale; 2012 Feb; 38(1):64-74. PubMed ID: 22381726
[TBL] [Abstract][Full Text] [Related]
20. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
Schanda H; Stompe T
Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
